









Markets
/
Stocks
/
nasdaq-pmn
/

ProMIS Neurosciences Inc

PMN

0.442USD

-0.015-3.39%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

14.43MMarket Cap

LossP/E TTM



ProMIS Neurosciences Inc

0.442

-0.015-3.39%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

130 / 506

Overall Ranking

236 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.625

Target Price

+1130.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 2.78M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -6.08, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 17.85M shares, decreasing 0.46% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.47.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.95, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.95

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -6.30, which is -88.29% below the recent high of -0.74 and 62.29% above the recent low of -2.37.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 130/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for ProMIS Neurosciences Inc is 5.00, with a high of 9.50 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.625

Target Price

+1174.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

ProMIS Neurosciences Inc

PMN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.73, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.55 and the support level at 0.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.73

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.011

Neutral

RSI(14)

41.555

Neutral

STOCH(KDJ)(9,3,3)

72.670

Buy

ATR(14)

0.042

High Vlolatility

CCI(14)

19.689

Neutral

Williams %R

67.114

Sell

TRIX(12,20)

-1.511

Sell

StochRSI(14)

69.030

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.439

Buy

MA10

0.431

Buy

MA20

0.469

Sell

MA50

0.591

Sell

MA100

0.548

Sell

MA200

0.684

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ally Bridge Group NY LLC

1.48M

-6.78%

Shaf QIC LLC

2.39M

Great Point Partners, LLC

2.65M

Title 19 ProMIS

3.02M

+45.46%

Armistice Capital LLC

2.33M

-6.98%

Sphera Funds Management Ltd.

1.93M

Sclar (Jeremy M.)

1.68M

Crocker Mountain LLC

1.16M

Shafmaster (Madge K.)

200.00K

Williams (Eugene Warren)

159.93K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.10, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.14. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.